Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report-Reference-Cited by-同舟云学术

Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report

Published:2018-12 Issue:1 Volume:18 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Cerveira Nuno^ORCID,Ferreira Rosa Branca,Bizarro Susana,Correia Cecília,Torres Lurdes,Lisboa Susana,Vieira Joana,Santos Rui,Campilho Fernando,Pinho Vaz Carlos,Leite Luís,Teixeira Manuel R.,Campos António

Funder

Incyte Corp

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-018-5100-4.pdf

Reference20 articles.

1. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med. 2003;349(15):1451–64.

2. Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A, et al. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1990;76(9):1819–24.

3. Wilson GA, Vandenberghe EA, Pollitt RC, Rees DC, Goodeve AC, Peake IR, et al. Are aberrant BCR-ABL transcripts more common than previously thought? Br J Haematol. 2000;111(4):1109–11.